Increased mortality among smokers with myelodysplastic syndrome (MDS)

Autor:	Ira Braunschweig, Amit Verma, Mendel Goldfinger, Ioannis Mantzaris, Noah Kornblum, Alejandro R. Sica, Phaedon D. Zavras, Lizamarie Bachier-Rodriguez, Aditi Shastri, Prateek Pophali
Rok vydání:	2021
Předmět:	Cancer Research medicine.medical_specialty Oncology business.industry hemic and lymphatic diseases Internal medicine medicine Risk factor business
Zdroj:	Journal of Clinical Oncology. 39:e19036-e19036
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2021.39.15_suppl.e19036
Popis:	e19036 Background: Recent studies have shown smoking to be an independent risk factor for MDS. We aimed to assess whether smoking is associated with worse outcomes among patients (pts) with MDS at Montefiore Medical Center, Bronx, NY. Methods: Pts with MDS and chronic myelomonocytic leukemia (CMML) diagnosed between June 16, 2000 and November 13, 2020 were analyzed. Those without available tissue diagnosis or smoking history data were excluded. Descriptive statistics compared ever-smokers to non-smokers. Cox PH regression was used to analyze the risk of transformation to acute myeloid leukemia (AML) and mortality in the 2 groups and multivariable analysis (MVA) adjusted for age, sex, de novo disease and R-IPSS. Results: A total of 147 pts were identified, 109 (74.1%) had a diagnosis of de novo MDS, 89 (60.5%) had history of active or former smoking and 58 (39.5%) were non-smokers. Smokers were predominantly males (66.3%) in contrast to non-smokers (37.9%) (p=0.001). Smokers were diagnosed more frequently with high or very high risk MDS, although the difference was not statistically significant (38.1% vs 28.6%, respectively; p=0.28). TP53 mutations were numerically more frequent among smokers (24.4%), compared to non-smokers (12.8%) (p=0.16). Median follow-up time for smokers and non-smokers was 19.4 and 31.4 months, respectively. In MVA, there was a trend for increased risk of AML transformation in smokers vs non-smokers (HR 2.03, 95% CI 0.99 – 4.15; p=0.052). Smokers with MDS were found to have significantly greater mortality compared to non-smokers (HR 2.08, 95% CI, 1.22 – 3.54; p=0.007). Conclusions: Smoking was associated with worse survival among MDS pts in our cohort. Although not significantly different, the prevalence of TP53 mutations was higher among smokers. Larger studies are warranted to confirm our findings.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5a4af738e51d9c2c9a5de539dea70fbc https://doi.org/10.1200/jco.2021.39.15_suppl.e19036 Zobrazit plný text záznamu